Home
Clinical Trials
A Study of Tucatinib Plus Tra...

A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer

Last Updated: 2025-09-30

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

70 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-12-01

Study Completion Date

2025-03-07

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This trial studies how well the drug tucatinib works when given with trastuzumab deruxtecan (T-DXd). It will also look at what side effects happen when these drugs are given together. A side effect is anything a drug does besides treating cancer.

Participants in this trial have HER2-positive (HER2+) breast cancer that has either spread to other parts of the body (metastatic) or cannot be removed completely with surgery (unresectable). All participants will get both tucatinib and T-DXd.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

NCT04579380

Uterine Neoplasms Uterine Cervical Neoplasms Biliary Tract Neoplasms +3 more

ACTIVE_NOT_RECRUITING PHASE2

Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer

NCT05748834

Breast Cancer

RECRUITING PHASE2

Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer

NCT05319873

Anatomic Stage II Breast Cancer AJCC v8 Anatomic Stage IIA Breast Cancer AJCC v8 Anatomic Stage IIB Breast Cancer AJCC v8 +17 more

RECRUITING PHASE1/PHASE2

A Study of Tucatinib (ONT-380) Combined With Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2+ Breast Cancer

NCT01983501

HER2 Positive Breast Cancers

COMPLETED PHASE1

A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer

NCT02614794

HER2 Positive Breast Cancer

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HER2 Positive Breast Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Single Arm

Tucatinib + trastuzumab deruxtecan

Group Type EXPERIMENTAL

tucatinib

Intervention Type DRUG

300 mg orally twice daily

trastuzumab deruxtecan

Intervention Type DRUG

5.4 mg/kg via intravenous (into the vein; IV) infusion on Day 1 of each of 21-day cycle

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

tucatinib

300 mg orally twice daily

Intervention Type DRUG

trastuzumab deruxtecan

5.4 mg/kg via intravenous (into the vein; IV) infusion on Day 1 of each of 21-day cycle

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

TUKYSA, ARRY-380, ONT-380 PF-07265792 T-DXd, Enhertu, DS-8201

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Have confirmed HER2+ breast cancer, as defined by the current American Society of Clinical Oncology - College of American Pathologists (ASCO/CAP) guidelines, previously determined at a Clinical Laboratory Improvements Amendments (CLIA)-certified or International Organization for Standardization (ISO)-accredited laboratory.
* History of prior treatment with a taxane and trastuzumab in the LA/M setting OR progressed within 6 months after neoadjuvant or adjuvant treatment, including a taxane and trastuzumab.
* Have progression of unresectable LA/M breast cancer after last systemic therapy (as confirmed by investigator), or be intolerant of last systemic therapy
* Have measurable disease assessable by RECIST v1.1
* Have Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0 or 1
* Have a life expectancy of at least 6 months, in the opinion of the investigator
* CNS Inclusion - Based on medical history and screening contrast brain magnetic resonance imaging (MRI), participants with a history of brain metastases must have one of the following:

* Untreated brain metastases not needing immediate local therapy. For participants with untreated central nervous system (CNS) lesions \>2.0 cm on screening contrast brain MRI, discussion with and approval from the medical monitor is required prior to enrollment
* Previously treated brain metastases

* Brain metastases previously treated with local therapy may either be stable since treatment or may have progressed since prior local CNS therapy, provided that there is no clinical indication for immediate re-treatment with local therapy in the opinion of the investigator
* Participants treated with CNS local therapy for newly identified or previously treated progressing lesions found on contrast brain MRI performed during screening for this study may be eligible to enroll if all of the following criteria are met:

* Time since whole brain radiation therapy (WBRT) is ≥14 days prior to first dose of study treatment, time since stereotactic radiosurgery (SRS) is ≥7 days prior to first dose of study treatment, or time since surgical resection is ≥28 days
* Other sites of measurable disease by RECIST v1.1 are present
* Relevant records of any CNS treatment must be available

Exclusion Criteria

* Have previously been treated with:

* Lapatinib or neratinib within 12 months of starting study treatment (except in cases where lapatinib or neratinib was given for ≤21 days and was discontinued for reasons other than disease progression or severe toxicity)
* Tucatinib or enrolled on a tucatinib clinical trial
* Any investigational HER2/epidermal growth factor receptor (EGFR) or HER2 tyrosine kinase inhibitor (TKI) (eg, afatinib) at any time previously
* Trastuzumab deruxtecan or another antibody-drug conjugate (ADC) consisting of an exatecan derivative
* Have received treatment with:

* Any systemic anti-cancer therapy (including hormonal therapy) or experimental agent ≤21 days of first dose of study treatment or are currently participating in another interventional clinical trial. An exception for the washout of hormonal therapies is gonadotropin releasing hormone (GnRH) agonists used for ovarian suppression in premenopausal women, which are permitted concomitant medications
* Treatment with non-CNS radiation ≤7 days prior to first dose of study treatment
* Major surgery \<28 days of first dose of study treatment
* Have clinically significant cardiopulmonary disease (such as history of iterstitial lung disease (ILD)/pneumonitis that required systemic corticosteroids, or have current ILD/pneumonitis, or where suspected ILD /pneumonitis cannot be ruled out be imaging at screening)
* Have known myocardial infarction or unstable angina within 6 months prior to first dose of study treatment
* Known to be positive for hepatitis B by surface antigen expression. Known to be positive for hepatitis C infection. Participants who have been treated for hepatitis C infection are permitted if they have documented sustained virologic response of 12 weeks
* Presence of known chronic liver disease
* Active or uncontrolled clinically serious infection
* Have inability to swallow pills or significant gastrointestinal disease which would preclude the adequate oral absorption of medications

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pfizer CT.gov Call Center

Role: STUDY_DIRECTOR

Pfizer

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University Of Alabama at Birmingham

Birmingham, Alabama, United States

Site Status

University of Alabama at Birmingham, IDS Pharmacy

Birmingham, Alabama, United States

Site Status

University Of Alabama at Birmingham

Birmingham, Alabama, United States

Site Status

Arizona Oncology Associates, PC - HOPE

Tucson, Arizona, United States

Site Status

Arizona Oncology Associates, PC - HOPE

Tucson, Arizona, United States

Site Status

UCLA Hematology/Oncology - Alhambra

Alhambra, California, United States

Site Status

UCLA Hematology/Oncology - Burbank

Burbank, California, United States

Site Status

City of Hope (City of Hope National Medical Center, City of Hope Medical center)

Duarte, California, United States

Site Status

City of Hope Investigational Drug Services (IDS)

Duarte, California, United States

Site Status

UCLA Hematology/Oncology - Laguna Hills

Laguna Hills, California, United States

Site Status

(IRB# 20-001502) Ronald Reagan UCLA Medical Center, Drug Information Center

Los Angeles, California, United States

Site Status

UCLA Hematology/Oncology

Los Angeles, California, United States

Site Status

UCLA Hematology/Oncology - Pasadena

Pasadena, California, United States

Site Status

Zuckerberg San Francisco General Hospital- Breast Clinic

San Francisco, California, United States

Site Status

Zuckerberg San Francisco General Hospital- Oncology Clinic

San Francisco, California, United States

Site Status

University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center

San Francisco, California, United States

Site Status

UCLA Hematology/Oncology - San Luis Obispo

San Luis Obispo, California, United States

Site Status

UCLA Hematology/Oncology - Santa Barbara

Santa Barbara, California, United States

Site Status

UCLA Hematology/Oncology - Santa Monica

Santa Monica, California, United States

Site Status

UCLA Hematology/Oncology Parkside

Santa Monica, California, United States

Site Status

UCLA Hematology/Oncology - Ventura

Ventura, California, United States

Site Status

UCLA Hematology/Oncology - Westlake

Westlake Village, California, United States

Site Status

University of Colorado Denver CTO/CTRC - Outpatient.

Aurora, Colorado, United States

Site Status

University of Colorado Hospital - Anschutz Cancer Pavilion (ACP)

Aurora, Colorado, United States

Site Status

University of Colorado Hospital - Anschutz Inpatient Pavilion (AIP)

Aurora, Colorado, United States

Site Status

University of Colorado Hospital - Anschutz Outpatient Pavilion (AOP)

Aurora, Colorado, United States

Site Status

UC Health Lone Tree Medical Center

Lone Tree, Colorado, United States

Site Status

Georgetown University Medical Center

Washington D.C., District of Columbia, United States

Site Status

Washington Cancer Institute at MedStar Washington Hospital Center

Washington D.C., District of Columbia, United States

Site Status

Florida Cancer Specialists

Altamonte Springs, Florida, United States

Site Status

Florida Cancer Specialists

Brandon, Florida, United States

Site Status

Florida Cancer Specialists

Clearwater, Florida, United States

Site Status

Florida Cancer Specialists

Gainesville, Florida, United States

Site Status

Florida Cancer Specialists

Largo, Florida, United States

Site Status

Florida Cancer Specialists

Lecanto, Florida, United States

Site Status

Florida Cancer Specialists

Ocala, Florida, United States

Site Status

Florida Cancer Specialists

Orange City, Florida, United States

Site Status

Florida Cancer Specialists

Orlando, Florida, United States

Site Status

Florida Cancer Specialists

St. Petersburg, Florida, United States

Site Status

Florida Cancer Specialists

Tampa, Florida, United States

Site Status

Florida Cancer Specialists

Tavares, Florida, United States

Site Status

Florida Cancer Specialists

The Villages, Florida, United States

Site Status

Florida Cancer Specialists

Trinity, Florida, United States

Site Status

Florida Cancer Specialists

Winter Park, Florida, United States

Site Status